11/4/2026

speaker
Conference Operator
Operator

Hello, everyone. Thank you for joining us and welcome to Schrodinger's conference call to review third quarter 2026 financial results. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, please press star one again. Please be advised that this call is being recorded at the company's request. Now, I would like to introduce your host for today's conference, Ms. Jaren Madden, Chief Corporate Affairs Officer and Head of Investor Relations. Please go ahead.

speaker
Jaren Madden
Chief Corporate Affairs Officer and Head of Investor Relations

Thank you, and good afternoon, everyone. Welcome to today's call, during which we will provide an update on the company and review our third quarter 2026 financial results. Earlier today, we issued a press release summarizing our financial results and progress across the company, which is available on our website at schrodinger.com. During today's call, management will make statements that are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including without limitation, statements related to our outlook for the full year 2026, our plans to accelerate the growth of our software business and advance our therapeutics portfolio, the capability and potential advantages of Bunsen, our agentic AI co-scientist, The clinical potential and properties of our compounds and those of our collaborators. The use of our cash resources as well as our future expenses. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects. which are based on the information currently available to us and on the assumptions we have made. Actual results may differ materially due to a number of important factors including the considerations described in the risk factors section and elsewhere in the filings we make with the SEC including our Form 10-Q for the quarter ended September 30, 2026. These forward-looking statements represent our views only as of today, and we caution you that, except as required by law, we may not update them in the future, whether as a result of new information, future events, or otherwise. Also included in today's call are certain non-GAAP financial measures. These non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and should be considered only in addition to and not a substitute for or superior to GAAP measures. Please refer to the tables at the end of our press release Karen Akinsanya, President, Head of Therapeutics R&D, and Chief Strategy Officer, Partnerships, will provide an update on our therapeutics portfolio. Pat Lorton, our Chief Technology and Chief Operating Officer, will join us for the Q&A. And with that, I will turn the call over to Ramy.

speaker
Ramy Farid
Chief Executive Officer

Thanks, Jaren, and thank you, everyone, for joining us today. Our third quarter results reflect sustained commercial momentum and strong progress toward the long-range goals we outlined earlier this year. ACV grew 17%, or 24%, excluding contribution ACV. Thank you so much for joining us. During the quarter, we received a milestone payment associated with the clinical progress of Structured Therapeutics Oral Small Molecule Amylin Program. On the strength of this performance, we are raising our full-year guidance for both ACV and drug discovery revenue. Looking across the molecular discovery landscape, biopharma and materials organizations are increasingly shifting toward a predict-first computational approach to increase the probability of success and shorten discovery timelines. As industries prioritize spending on the most high-impact solutions, our platform remains critical to molecular discovery, enabling us to deliver durable growth. While the promise of AI in molecular discovery is immense, Thank you for watching. With the introduction of Bunsen, we are now deploying agentic AI to orchestrate our computational platform to increase efficiency and broaden user adoption across life sciences and material science. Customer interest has been very strong, and the feedback from our Early Access program has been enthusiastically positive with multiple customers in the process of evaluating the solution. Within Schrodinger, Bunsen has rapidly become the primary interface for discovery workflows and now handles approximately 80% of our high throughput calculations on our internal compute cluster. Our predictive toxicology solution also continues to be an important part of our strategy to expand the capabilities of our platform. Thank you for watching. Commercial evaluations are progressing well. We expect the adoption curve to follow the path of our foundational tools like FEP+, where thorough customer benchmarking requires diligence upfront, but ultimately establishes deeply integrated, highly entrenched software adoption that endures as the industry standard. We are very pleased with the progress we are making in material science. Customers across a broad range of industries, including chemicals, energy storage, semiconductors and electronics, are increasing their use of our platform. By using our platform, scientists can accurately predict critical properties such as stability, conductivity and mechanical performance prior to physical testing. Material science is an important long-term growth driver that significantly expands our software market beyond drug discovery. We continue to make scientific advancements in this area. Last month, we published breakthrough research in Nature that revealed critical insights in the fundamental chemistry of lithium batteries. Using our machine learning force fields, our team simulated battery electrolytes at unprecedented accuracy, paving the way for for the computational design of higher capacity, faster charging, and longer lasting batteries. Additionally, our researchers recently published a novel method for accurately predicting the stability of organic electronic materials for OLED displays. Thank you for joining us. Approval is expected early next year, further reinforcing our track record of success. During the quarter, we launched Tektora, a discovery stage company funded with $55 million for NEA and RA Capital and anchored by two programs originated by our therapeutics team. Tektora is the latest company built through our co-founding strategy, which has already produced a number of clinical successes and allows us to share in long-term value through equity, milestones, and royalties. Thank you, Ramy, and good afternoon. Our third quarter results highlight the ongoing momentum across our business, marked by strong ACV growth, continued transition to hosted licenses,

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API